Results 131 to 140 of about 1,483,959 (183)

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

open access: yesBlood
Uchida T   +13 more
europepmc   +1 more source

Prevalence of definite antiphospholipid syndrome in carriers of the JAK2V617F mutation.

Thrombosis Research, 2020
INTRODUCTION Patients with Philadelphia-negative myeloproliferative neoplasms (MPNs), particularly those carrying the JAK2V617F mutation, are at increased risk of thrombosis.
Snjezana Janjetovic   +9 more
semanticscholar   +3 more sources

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms

Leukemia, 2017
The JAK2 V617F mutation is a target for specific T cells in the JAK2 V617F-positive myeloproliferative ...
M. Holmström   +9 more
semanticscholar   +4 more sources

JAK2V617F Mutation in Patients With Portal Vein Thrombosis

Digestive Diseases and Sciences, 2008
In a retrospective cohort, we investigated the presence of the JAK2V617F mutation in chronic non-cirrhotic portal vein thrombosis (PVT) patients, irrespective of the presence or absence of myeloproliferative diseases (MPDs). We identified 25 patients in whom thrombophilia workup was completed.
Ali Shorbagi   +2 more
exaly   +4 more sources

Profile of plasma free amino acids, carnitine and acylcarnitines, and JAK2v617f mutation as potential metabolic markers in children with type 1 diabetic nephropathy.

Biomedical chromotography, 2023
Fifty diabetic nephropathy (DN) children with type 1 diabetes mellitus (T1DM) and 50 healthy matched controls were included. Chromatographic assays of 14 amino acids, free carnitine and 27 carnitine esters using high-performance liquid chromatography ...
Mohammed H. Hassan   +6 more
semanticscholar   +1 more source

Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation?

Journal of Oncology Pharmacy Practice, 2021
Introduction Diagnoses of myeloproliferative disorder is based on molecular marker. Chronic Myeloid Leukemia and Myeloproliferative neoplasms were considered mutually exclusive and co-existence of BCR/ABL1 and JAK2 mutation is a rare phenomenon.
R. Frikha   +4 more
semanticscholar   +1 more source

Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms

Der Pathologe, 2016
Chronic myeloproliferative neoplasms (MPN) comprise a spectrum of clonal neoplastic disorders characterized by overproduction of terminally differentiated cells of the myeloid lineage. A common genetic basis for the BCR-ABL-negative MPN disorders was elucidated in 2005 with the identification of the JAK2V617F mutation in the majority of MPN patients ...
A. Mullally
semanticscholar   +3 more sources

JAK2V617F Mutation in Patients with Splanchnic Vein Thrombosis

Digestive Diseases and Sciences, 2009
Splanchnic vein thrombosis can be the presenting manifestation of myeloproliferative neoplasms. However, the diagnosis of a myeloproliferative neoplasm in these patients is often problematic, and more objective criteria are needed.To determine the frequency of the mutation JAK2V617F in patients with splanchnic vein thromboses.A consecutive series of ...
Sandra Guerra, Xavier   +8 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy